Ending the Neglect of Chagas in Colombia
Ending the Neglect of Chagas in Colombia
Hidden in the mountains, forests, and pastures of the central Andean region in Colombia are small, remote communities where Chagas disease still takes a heavy toll.
Ending the Neglect of Chagas in Colombia
DNDi agreement with Colombia Ministry of Health and Social Welfare to guarantee access to comprehensive care for Chagas patients
Bogotá, Colombia - 14 April 2018 Objective is to improve access to diagnosis and treatment of people affected by this disease An agreement to facilitate and strengthen access to diagnosis and treatment of patients with Chagas and other diseases of public health interest has been signed by the Colombian Ministry of Health and Social Protection and the non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi).
DNDi agreement with Colombia Ministry of Health and Social Welfare to guarantee access to comprehensive care for Chagas patients
Drug approved in Argentina for treatment of Chagas disease in children
Buenos Aires, Argentina - 13 April 2018 Argentina has approved the paediatric indication of a drug used for treatment of Chagas disease, benznidazole, which will now be available in 12.5 mg pills, the dose required to treat children under the age of 2. The indication was approved by the Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT).
Drug approved in Argentina for treatment of Chagas disease in children
Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa
Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa
Addis Ababa - 13 April 2018 Study launched as part of new Afri-KA-DIA Consortium will also assess diagnostic tools A new study to find a safer, efficacious and more patient-friendly treatment and improved diagnostic tools for people living with visceral leishmaniasis (VL) has begun in eastern Africa, within the new Afri-KA-DIA consortium with funding from The European & Developing Countries Clinical Trials Partnership (EDCTP). The large-scale Phase III clinical trial seeks to assess the efficacy and safety of a combination of miltefosine and paromomycin in treating VL in eastern Africa.
Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa
See all news

Scientific Articles

See all scientific articles

Events

  • The International Liver Congress 2018 11-15 April 2018 Paris, France Isabelle Andrieux-Meyer, Head of Clinical Development, Paediatric HIV/HCV Programmes - poster presentation of results of the STORM-C-1 phase II/III trial
  • DIA Europe 2018 17-19 April 2018 Basel, Switzerland Nathalie Strub-Wourgraft, DNDi Medical Director – Member of multi-stakeholder panel: “Towards access 2030: How can strengthening of regulatory systems contribute?”
  • 28th European Congress of Clinical Microbiology and Infectious Diseases 21-24 April 2018 Madrid, Spain Monique Wasunna, Director, DNDi Africa – presentation on visceral leishmaniasis in a session on Africa & Middle East
  • MSF Scientific Days 2018 24-25 May 2018 London, UK Olawale Salami, Paediatric HIV Clinical Project Manager DNDi Africa - presentation of the LIVING study on treatment for paediatric HIV Leishmaniasis Team, DNDi - presentation on PKDL in the Indian subcontinent Jorge Alvar, Senior Leishmaniasis Advisor, DNDi - presentation on HIV-VL in East Africa
See all events